Fig. 5: Metformin resumes the sensitivity of CD34+ CML cells to imatinib in the PDX model. | Cell Death & Disease

Fig. 5: Metformin resumes the sensitivity of CD34+ CML cells to imatinib in the PDX model.

From: Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells

Fig. 5

A Diagram of experimental design. The engraftment of CML CD34+ cells in mice were assessed by monitoring the percentage of human CD45+ circulating leukocytes using flow cytometry. B, C Percentages of human CD45+CD34+ cells in the bone marrow post transplantation are shown. D Survival of the CML PDX mice with indicated treatment was shown. E The leukemic invasions in the spleen and liver of PDX mice with indicated treatment were analyzed by hematoxylin and eosin (H&E) staining.

Back to article page